Baudax Bio, Inc.
BXRXQ · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -1,357.84% | -3,145.57% | -8,954.69% | -22,491.13% |
| EV / EBITDA | -1.46 | -1.85 | -0.79 | -0.25 |
| Quality | ||||
| ROIC | -25.01% | -96.06% | -675.50% | 147.55% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -1,445.81% |
| Cash Conversion Ratio | 1.28 | 0.47 | 0.63 | 0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | -25.71% | 0.31% | 7.06% | 37.08% |
| Free Cash Flow Growth | 29.37% | 26.11% | -23.29% | 2.70% |
| Safety | ||||
| Net Debt / EBITDA | -1.43 | -1.82 | -0.77 | -0.25 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,647.56 | -10,490.40 | -115,110.00 | 23.50 |